

# REGENERON

November 11, 2016

## Regeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016

TARRYTOWN, N.Y. and BRIDGEWATER, N.J., Nov. 11, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: **REGN**) and Sanofi today announced that data from the Praluent® (alirocumab) Injection ODYSSEY clinical trial program will be presented at the American Heart Association's (AHA) Scientific Sessions 2016 in New Orleans, Louisiana, from November 12-16.

# REGENERON

Analyses of pooled data from the pivotal Phase 3 ODYSSEY clinical trial program include a presentation on the ability for patients to attain their LDL cholesterol goals with Praluent versus ezetimibe. An analysis from the ODYSSEY CHOICE I trial evaluating Praluent as a monthly (every four weeks) dose will also be presented. Other data presentations evaluate the real world use or potential health impact of PCSK9 inhibitors and other lipid-lowering therapies.

Praluent is a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C. The effect of Praluent on cardiovascular morbidity and mortality has not been determined. Praluent is contraindicated in patients with a history of a serious hypersensitivity reaction to Praluent. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization.

Sanofi and Regeneron data is featured in 16 abstracts at the AHA Scientific Sessions 2016. Key data highlights include:

### Praluent data:

#### 1) ORAL PRESENTATION

##### ┆ **Metabolic Syndrome, Dysglycemia, and Dyslipidemia: Diagnostic, Prognostic, and Therapeutic Aspects**

- ┆ Pharmacodynamic Relationship Between PCSK9, Alirocumab, and LDL-C Lowering in the ODYSSEY CHOICE I Trial (Roth)
  - ┆ Abstract # 685
  - ┆ Monday, November 14, 2:00-2:05 p.m. CT (Science and Technology Hall, Population Science Theater)

#### 2) POSTER PRESENTATIONS

##### ┆ **Preventive Interventions: Population and Clinical Trials**

- ┆ Treatment Effect of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia With Baseline Low-density Lipoprotein Cholesterol Levels > 130 mg/dL Receiving High Intensity Statin (Kastelein)
  - ┆ Abstract # M2013
  - ┆ Monday, November 14, 10:45 a.m.-12:00 p.m. CT (Science and Technology Hall, Population Science Section)
- ┆ Comparison of Low-density Lipoprotein Cholesterol Threshold Attainment With Alirocumab versus Ezetimibe Treatment in the ODYSSEY Program (Cannon)
  - ┆ Abstract # M2014
  - ┆ Monday, November 14, 10:45 a.m.-12:00 p.m. CT (Science and Technology Hall, Population Science Section)

### Additional data of interest:

#### 1) ORAL PRESENTATION

## 1 Risk Assessment and Prevention

- i Impact of Communication Format and Risk Horizon on Patient Perceptions of CVD Risk: Findings From the PALM Registry (Navar)
  - n Abstract # 781
  - n Tuesday, November 15, 12:20-12:25 p.m. CT (Science and Technology Hall, Population Science Theater)

## 2) POSTER PRESENTATIONS

### 1 Epidemiology and Population Studies in Cardiovascular Disease Session I

- i From Clinical Trial to Clinical Setting: What are the Observed Prescribing Behaviors in the United States Since the Launch of PCSK9 Inhibitors? (Karalis)
  - n Abstract # S2167
  - n Sunday, November 13, 3:45-5:00 p.m. CT (Science and Technology Hall, Population Science Section)

### 1 Epidemiology and Population Studies: Statins and Statin Adherence

- i Simulation of Impact on Cardiovascular Events With Lipid-lowering Treatment Intensification in Patients With Atherosclerotic Cardiovascular Disease in the US (Cannon)
  - n Abstract # T2014
  - n Tuesday, November 15, 10:45 a.m.-12:00 p.m. CT (Science and Technology Hall, Population Science Section)

Further information on AHA Scientific Sessions 2016 is available on the congress [website](#).

## About Praluent

Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which results in lower LDL cholesterol levels in the blood. Praluent is the only PCSK9 inhibitor available in two dosages with two levels of efficacy (75 mg and 150 mg), allowing physicians to select the dose based on a patient's LDL cholesterol lowering needs.

Praluent is approved in approximately 40 countries worldwide, including the U.S., Japan, Canada, Switzerland, Mexico, Brazil and the European Union (EU). In the U.S., Praluent is approved for use as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical atherosclerotic CV disease, who require additional lowering of LDL cholesterol. In the E.U., Praluent is approved for the treatment of adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet: **a**) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach their LDL cholesterol goals with the maximally-tolerated statin or **b**) alone or in combination with other lipid-lowering therapies for patients who are statin intolerant, or for whom a statin is contraindicated. The effect of Praluent on CV morbidity and mortality has not yet been determined. ODYSSEY OUTCOMES is prospectively evaluating the effect of Praluent on the occurrence of CV events in approximately 18,000 patients who have experienced an acute coronary syndrome.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

## Important Safety Information for the U.S.

Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT.

Before you start using PRALUENT, tell your healthcare provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.

Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies.

PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing.

The most common side effects of PRALUENT include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Talk to your doctor about the right way to prepare and give yourself a PRALUENT injection and follow the "Instructions for Use" that comes with Praluent.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please click [here](#) for the full Prescribing Information

### **About Sanofi**

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

### **About Regeneron Pharmaceuticals, Inc.**

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit [www.regeneron.com](http://www.regeneron.com) or follow @Regeneron on Twitter.

### **Sanofi Forward-Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

### **Regeneron Forward-Looking Statements and Use of Digital Media**

*This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation Praluent<sup>®</sup> (alirocumab) Injection; unforeseen safety issues and possible liability resulting from the administration of products (including without limitation Praluent) and product candidates in patients; serious complications or side effects in connection with the use of Regeneron's products and product candidates in clinical trials, such as the ODYSSEY OUTCOMES trial prospectively assessing the potential of Praluent to demonstrate cardiovascular benefit; coverage and reimbursement determinations by third-party payers, including Medicare, Medicaid, and pharmacy benefit management companies; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as Praluent), research and clinical programs, and business, including those relating to the enrollment, completion, and meeting of the relevant endpoints of post-approval studies (such as the ODYSSEY OUTCOMES trial); determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products; competing drugs and product candidates that may be superior to Regeneron's products and product candidates;*

*uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2015 and its Form 10-Q for the quarterly period ended September 30, 2016. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.*

*Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (<http://newsroom.regeneron.com>) and its Twitter feed (<http://twitter.com/regeneron>).*

**Contacts Sanofi:**

**Media Relations**

Katherine Hamlet

Tel: +1 (908) 981-5848

Mobile: +1 (215) 219-9087

[Katherine.Hamlet@sanofi.com](mailto:Katherine.Hamlet@sanofi.com)

**Contacts Regeneron:**

**Media Relations**

Arleen Goldenberg

Tel: + 1 (914) 847-3456

Mobile: +1 (914) 260-8788

[Arleen.Goldenberg@regeneron.com](mailto:Arleen.Goldenberg@regeneron.com)

Logo - <http://photos.prnewswire.com/prnh/20160801/394535LOGO>

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/regeneron-and-sanofi-to-present-data-from-phase-3-praluent-alirocumab-injection-clinical-trials-at-aha-scientific-sessions-2016-300361313.html>

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media